题名 | OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study | 链接 | http://ard.bmj.com/content/74/Suppl_2/75.3 |
Ann Rheum Dis 2015;74:75-76 doi:10.1136/annrheumdis-2015-eular.1427
|